Koc Irene, Bagheri Saghar, Chau Rachel K, Hoyek Sandra, Shousha Nour Abou, Mahmoudinezhad Golnoush, Falcone Michelle M, Oke Isdin, Hunter David G, Patel Nimesh A
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Ophthalmology. 2025 Jun;132(6):654-660. doi: 10.1016/j.ophtha.2024.12.037. Epub 2025 Jan 3.
To evaluate the cost-utility of Luminopia (Luminopia, Inc) and CureSight (NovaSight, Ltd) as therapy for amblyopia compared with current common amblyopic treatments such as glasses, atropine drops, and patching.
Cost analysis based on data from published randomized control trials (RCTs).
Data from Luminopia, CureSight, and atropine RCTs.
A cost-utility analysis was performed using patient preference-based time trade-off utility values from previous literature. Costs for eye examinations were calculated using reimbursement data; device costs for duration of treatment were provided by sales representatives of Luminopia and CureSight. All treatments were inclusive of the cost of eyeglasses. Visual acuity (VA) and stereoacuity outcomes were extrapolated from the RCTs for atropine, Luminopia, and CureSight. A quality-adjusted life-year (QALY) was calculated by multiplying utility gain, a value correlated with VA gain, by length of time of benefit.
Cost, cost per QALY, and cost per stereoacuity gain.
The cost to treat amblyopia with glasses alone for 12 weeks was $514. The cost of treating with patching for 12 weeks was $540 and with atropine for 16 weeks was $652, whereas the cost of treating with Luminopia or CureSight for 12 weeks was $1951 and $1564 or $1814, respectively. Treatment with glasses alone or patching for 12 weeks resulted in a cost per QALY gained of $427 and $101, respectively. Atropine treatment for 16 weeks resulted in a cost per QALY gained of $151. The cost per QALY for 12-week Luminopia treatment was $618 versus $368 or $427 for 12-week CureSight treatment and $314 or $354 for 16-week CureSight treatment (P < 0.05). Cost per stereoacuity gain for 12-week treatment duration was $6421/log arcsec (glasses), $1801/log arcsec (patching), and $3007/log arcsec or $3488/log arcsec (CureSight).
Treatment of amblyopia with Luminopia or CureSight is cost-effective in comparison with established willingness-to-pay thresholds and can provide a viable treatment option, especially for those who are unable to tolerate patching or atropine penalization. Cost-effectiveness values based on VA gain of Luminopia and CureSight were comparable.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
评估Luminopia（Luminopia公司）和CureSight（NovaSight有限公司）作为弱视治疗方法相对于当前常见的弱视治疗方法（如眼镜、阿托品滴眼液和遮盖疗法）的成本效益。
基于已发表的随机对照试验（RCT）数据进行成本分析。
Luminopia、CureSight和阿托品RCT的数据。
使用先前文献中基于患者偏好的时间权衡效用值进行成本效益分析。眼科检查费用使用报销数据计算；Luminopia和CureSight的销售代表提供治疗期间的设备成本。所有治疗均包括眼镜成本。视力（VA）和立体视锐度结果从阿托品、Luminopia和CureSight的RCT中推断得出。通过将与VA增益相关的值效用增益乘以受益时间长度来计算质量调整生命年（QALY）。
成本、每QALY成本和每立体视锐度增益成本。
仅用眼镜治疗弱视12周的成本为514美元。遮盖治疗12周的成本为540美元，阿托品治疗16周的成本为652美元，而用Luminopia或CureSight治疗12周的成本分别为1951美元、1564美元或1814美元。仅用眼镜或遮盖治疗12周，每获得一个QALY的成本分别为427美元和101美元。阿托品治疗16周，每获得一个QALY的成本为151美元。Luminopia治疗12周每QALY的成本为618美元，而CureSight治疗12周为368美元或427美元，CureSight治疗16周为314美元或354美元（P<0.05）。治疗12周每立体视锐度增益的成本为6421美元/对数角秒（眼镜）、1801美元/对数角秒（遮盖）以及3007美元/对数角秒或3488美元/对数角秒（CureSight）。
与既定的支付意愿阈值相比，使用Luminopia或CureSight治疗弱视具有成本效益，并且可以提供一种可行的治疗选择，特别是对于那些无法耐受遮盖或阿托品抑制疗法的患者。基于Luminopia和CureSight的VA增益的成本效益值具有可比性。
在本文末尾的脚注和披露中可能会发现专有或商业披露信息。
